Figure 5. Prognostic validation of MLXIPL and PPARGC1A in FUSCC cohort. (A–B) To validate AQP9 mRNA expression profile in ccRCC tissues, we performed RT-qPCR using 380 paired tumor and normal samples with available clinical follow-up data from a real-world cohort. It revealed dramatically increased MLXIPL and decreased PPARGC1A mRNA expression in ccRCC samples than normal tissues. (C–F) Survival curves suggested that patients with elevated MLXIPL and decreased PPARGC1A mRNA levels significantly correlated with poorer PFS and OS (p<0.001).